INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2025

Cocoa flavanol supplementation for a median of 3.6 years did not significantly reduce the overall risk of AMD in older adults.

As an ancillary study of the COSMOS trial, 21,442 older US adults were randomized to receive a daily cocoa extract supplement (500 mg/day flavanols, including 80 mg (-)-epicatechin) or placebo. Over a median of 3.6 years, 344 participants experienced a confirmed AMD event. There were 159 cases (1.5%) in the cocoa extract group compared to 185 cases (1.7%) in the placebo group, showing no significant overall effect (HR, 0.87; 95% CI, 0.71-1.08; P = .21). Due to nonproportional hazards, separate models suggested a reduced risk during the first 2 years (HR, 0.77; 95% CI, 0.59-1.01) but no benefit beyond 2 years (HR, 1.06; 95% CI, 0.76-1.50).

Study type
Double-blind, placebo-controlled, 2x2 factorial randomized trial
Who was studied
21,442 US adults (12,666 women aged 65+ and 8,776 men aged 60+)
What was measured
Composite of incident age-related macular degeneration (AMD) plus progression to advanced AMD

THE PAPER

Cocoa Flavanol Supplementation and Risk of Age-Related Macular Degeneration: An Ancillary Study of the COSMOS Randomized Clinical Trial.

Christen WG, Rist PM, Moorthy MV, Smith DC, Holman B, Clar A, Glynn RJ, Mares JA, Sobrin L, Shadyab AH, Allison MA, Millen AE, Manson JE, Sesso HD, COSMOS Research Group. JAMA Ophthalmol, 2025.

PubMed 40146119 ↗DOI 10.1038/s41598-017-09421-9 ↗

Healthy aging & longevityOther health

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.